Trial reportCancer research communications2022
A randomized clinical trial of precision prevention materials incorporating
Trial report in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Predictors of correct recall of genetic risk information among Hispanic individuals in Florida and Puerto Rico.Patient education and counseling · 2023Trial
- Predictors of genetic risk recall among the participants of a randomized controlled precision prevention trial against melanoma.Genetics in medicine : official journal of the American College of Medical Genetics · 2023Trial
- Assessment of skin cancer precision prevention materials among Hispanics in Florida and Puerto Rico.Patient education and counseling · 2022Trial
- Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Assessment of melanoma precision prevention materials incorporating MC1R genetic risk information.Translational behavioral medicine · 2022Trial
- Effects of polygenic risk score communication on short term health outcomes: systematic review and meta-analysis.BMJ medicine · 2026Article
- Prospective changes in primary care patients' family communication after skin cancer genetic test offer.PEC innovation · 2025Article
- Article
- Sharing and seeking information about skin cancer risk and prevention among Hispanic people from Florida and Puerto Rico.PEC innovation · 2023Article
- Qualitative assessment of uptake retention and evaluation of prevention materials for skin cancer among Hispanics.Patient education and counseling · 2023Article
- Associations between social COVID-19 exposure and psychological functioning.Journal of behavioral medicine · 2023Article
- Precision Public Health Initiatives in Cancer: Proceedings from the Transdisciplinary Conference for Future Leaders in Precision Public Health.BMC proceedings · 2022Article
- Cutaneous Oncology: Strategies for Melanoma Prevention, Diagnosis, and Therapy.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Purpose: Skin cancer incidence is increasing among Hispanics, who experience worse outcomes than non-Hispanic Whites. Precision prevention incorporating genetic testing for Patients and Methods: Hispanic participants (n=920) from Tampa, FL and Ponce, PR, were block-randomized within Results: Among Conclusions: Receipt of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.